Evidence map›Paper›PMID 37151965›Full record

ArticleFrontiers in psychiatry2023

Pregnant individual's lived experience of cannabis use during the COVID-19 pandemic: a qualitative study.

Kelly C Young-Wolff, Tara R Foti, Andrea Green, Esti Iturralde, Melanie Jackson-Morris, Monique B Does, Sara R Adams, Nancy Goler, Amy Conway, Deborah Ansley and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kelly C Young-WolffDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
Tara R FotiDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
Andrea GreenSacramento Medical Center, Kaiser Permanente Northern California, Sacramento CA, United States.
Esti IturraldeDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
Melanie Jackson-MorrisDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
Monique B DoesDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
Sara R AdamsDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
Nancy GolerRegional Offices, Kaiser Permanente Northern California, Oakland CA, United States.
Amy ConwayRegional Offices, Kaiser Permanente Northern California, Oakland CA, United States.
Deborah AnsleyRegional Offices, Kaiser Permanente Northern California, Oakland CA, United States.
Andrea AltschulerDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
Kaiser Permanente · USKaiser Permanente Sacramento Medical Center · US

Funding

Identifying Risk Factors for Prenatal Substance and Polysubstance UseK01DA043604 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI YOUNG-WOLFF, KELLY CORINNE · 2017 to 2021
$907k
NIDA NIH HHS K01 DA043604
6 · The paper itself

Abstract

Introduction: Quantitative studies indicate that the COVID-19 pandemic has contributed to increased rates of prenatal cannabis use. However, little is known about how the pandemic has impacted cannabis use from the perspective of pregnant individuals themselves. Our objective was to characterize COVID-19-related changes in cannabis use among pregnant individuals who used cannabis during the pandemic. Methods: We conducted 18 focus groups (from 11/17/2021 to 12/17/2021) with Black and White pregnant individuals aged 18+ who self-reported prenatal cannabis use during universal screening at entrance to prenatal care (at ~8 weeks gestation) in Kaiser Permanente Northern California. Virtual focus groups were transcribed and analyzed using thematic analysis. Results: The sample of 53 pregnant individuals (23 Black, 30 White) was 30.3  years old (SD = 5.2) on average, and most (70%) self-reported daily versus weekly or monthly prenatal cannabis use. Major themes regarding the impact of the pandemic on cannabis use included increases in use (resulting from depression, anxiety, stress, boredom), and changes in social use (less sharing of smoked cannabis products), modes of use (from smoking to other modes due to respiratory concerns) and source (from storefront retailers to delivery). Conclusion: Coping with mental health symptoms and stress were identified drivers of perceived pandemic-related increases in prenatal cannabis use in 2021. Pregnant individuals adapted their use in ways consistent with public health recommendations to decrease social contact and reduce or quit smoking to mitigate COVID-19 transmission and harms. Proactive, mental health outreach for pregnant individuals during future pandemic waves may reduce prenatal cannabis use.

Indexed as

cannabisCOVID-19focus groupmarijuanapandemicpregnancyprenatal

Identifiers

PMID37151965
PMCPMC10160679
OpenAlexW4366771167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.